Eli Lilly's Stock Is Trading Lower After Donanemab Showed Mixed Data In Mid-Stage Alzheimer's Study

Eli Lilly and Co LLY gave an in-depth look at its donanemab Phase 2 trial in Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases.

  • As announced in January, the drug met the trial’s primary goal by slowing down the rate of cognitive and daily function decline by 32% compared to a placebo. But it missed the mark on several secondary tests.
  • Donanemab is a monoclonal antibody that was designed to target tau and amyloid plaque, Alzheimer’s-associated proteins.
  • New data also showed that donanemab slowed the accumulation of tau and substantially cleared amyloid plaques from the brains of the majority of patients.
  • Alzheimer’s in the trial sustained the same level of cognitive skills after 18 months of donanemab treatment as the placebo group showed after 12 months.
  • On secondary goals of the study, while patients on the drug did numerically better on various other cognitive and functional scales than placebo, the differences weren’t statistically significant in some cases.
  • The new data maintains its safety meets standards; noted side effects had included “amyloid-related” swelling in the brain.
  • Price Action: LLY shares decreased 7.01% at $193.5 in premarket trading on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralAlzheimer’sPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!